Table 3. Characteristics of psoriatic arthritis patients with (ambiguous and likely) and without neuropathic pain.
| Patients with NP | Patients without NP | P | |||
|---|---|---|---|---|---|
| Median | IQR | Median | IQR | ||
| Age (year) | 53.5 | 17 | 46.5 | 17 | 0.38 |
| Body mass index (kg/m2) | 23.8 | 5.8 | 27.8 | 3.8 | 0.21 |
| Disease duration (month) | 60 | 99 | 48 | 60 | 0.59 |
| DAS-28 | 3.6 | 1.7 | 2.5 | 0.8 | <0.0001 |
| Erythrocyte sedimentation rate (mm/h) | 23 | 18 | 21.5 | 20 | 0.86 |
| C-reactive protein (N <5 mg/L) | 3 | 3.7 | 3 | 5 | 0.94 |
| VAS-pain | 8 | 4 | 2 | 4 | <0.0001 |
| PSQI total score | 10 | 7 | 4 | 9 | 0.002 |
| PsAQoL | 13 | 7.5 | 4.5 | 7 | 0.01 |
| MAF | 31.5 | 27.2 | 16.3 | 25 | 0.03 |
| NP: Neuropathic pain; IQR: Interquartile range; DAS-28: Disease activity score; VAS: Visual analog scale; PSQI: Pittsburgh Sleep Quality Index; PsA: Psoriatic arthritis; PsAQoL: Psoriatic Arthritis Quality of Life; MAF: Multidimensional Assessment of Fatigue. | |||||